The evolving role of gemcitabine in the management of breast cancer

Oncology

Volumn 60, Issue 3, 2001, Pages 189-198

  Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

2 ,2 difluorodeoxycytidine; Breast cancer; Chemotherapy; Gemcitabine; Phase II studies

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; NUCLEOSIDE DERIVATIVE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMATOLOGIC DISEASE; HUMAN; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS;

EID: 0035004278     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055318     Document Type: Review

References (46)

1. Endocrine therapy of breast cancer
2. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
3. Combining chemotherapy and radiotherapy for metastatic breast cancer: Opportunities and obstacles
4. Docetaxel and paclitaxel in breast cancer therapy: Present status and future prospects
5. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
6. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
7. A phase III trial comparing doxorubicin (A) and docetaxel (T) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC
8. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
9. Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials
10. Management of metastatic breast cancer: Reasons for optimism
11. Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An intergroup trial
12. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy
13. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as frontline therapy in untreated metastatic breast cancer
14. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
15. Balance of time to progression, quality of life, and overall survival: More gain from treatment in single agent treatment with mitoxantrone (N) than with the combination of fluorouracil, epirubicin, cyclophosphamide (FEC) Results of a multicenter randomized trial in high risk metastatic breast cancer
16. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER-2+) metastatic breast cancer (MBC)
17. Capecitabine in combination with docetaxel: Clinical studies in patients with metastatic breast cancer
18. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
19. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer
20. Mechanism of action of 2′,2′-deoxycytidine triphosphate on DNA synthesis
21. Evaluation of the antitumor activity of gemcitabine (difluoro-2′-deoxycytidine)
22. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
23. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
24. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer
25. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
26. Advanced breast cancer: A phase II trial with gemcitabine
27. Phase II study of gemcitabine in patients with metastatic breast cancer
28. Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline containing regimens
29. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
30. Interactions of cis-diamminedichloroplatinum (II) with 1-beta-D-arabinofuranosylcytosine in LoVo colon carcinoma cells
31. Synergistic interactions between cisplatin and gemcitabine in ovarian and colon cancer cell lines
32. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
33. Significant activity of gemcitabine (Gem) and cis-platin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): A California Cancer Consortium/Loyola University Chicago Trial
34. Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer and failure on prior chemotherapy: A North Central Cancer Treatment Group Trial
35. Monthly cisplatin and gemcitabine as second line chemotherapy for patients with advanced breast cancer
36. Dose-finding study of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MBC)
37. A phase II study of gemcitabine (G) and vinorelbine (V) in patients with advanced breast cancer (ABC)
38. Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial
39. Gemzar (G) and epirubicin (E) in patients (Pts) with metastatic breast cancer (MBC): Final results of a phase I dose finding study
40. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer (MBC)
41. Biweekly paclitaxel and gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain
42. Weekly schedule of gemcitabine (G) plus docetaxel (D) in refractory advanced breast cancer (Bc): A dose-finding study
43. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (Pts) with metastatic breast cancer (MBC): A phase II study
44. Gemcitabine, epirubicin, and taxol (GET) followed by high dose chemotherapy (HDCT): High activity with good tolerability in metastatic breast cancer patients
45. The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer
46. Biweekly gemcitabine-adriamycin-paclitaxel combination (GAT) in metastatic breast cancer patients (MBC): Results from a phase II trial